Here's the hot stuff from Intuitive Surgical $ISRG (-0,96%)
(NASDAQ: ISRG) Q3 2026 Earnings Release, fresh off the US market close:
🚀 Top-line revenue at a record high
Intuitive Surgical once again posted strong growth in the third quarter of 2026:
- Revenue:
$3.05 billion → +21.5% YoY
(Previous year: $2.51 billion) - Expectations were around $2.91 billion → ISRG significantly beat estimates by over $140 million.
- Instruments & Accessories: The main driver of revenue thanks to extremely high surgery rates.
The key point: ISRG is not only growing through the sale of new robotic systems but is also massively boosting high-margin repeat business (consumables) through rising surgery rates in the installed base.
đź’° The cash flow machine continues to scale
The robotics pioneer is also delivering impressive results on the bottom line:
- Non-GAAP EPS:
$3.00 → +25.0% YoY
(Previous year: $2.40) - Expected: $2.65 → A beat of a fantastic +0.35 USD per share!
- Net Income (Non-GAAP):
$1.05 billion
(prior year: $867 million) - Gross Margin: Solid, in the range of ~68.5% – 69%.
And this is where things get really impressive: ISRG breaks the $3 billion in quarterly revenue and converts over 1 billion USD of that directly into net income.
🦾 Procedure Growth = The Real Powerhouse
The most important point in the entire report on MedTech stocks:
Global da Vinci procedure growth = +18% YoY.
This corresponds to:
- A steady double-digit increase in the number of surgeries worldwide.
- Ion System: Continues to be a major growth driver in the lung biopsy segment.
This is the metric I would monitor most closely at Intuitive Surgical—not just system sales.
As long as hospitals use the systems more intensively, high-margin cash flow from instruments and services will automatically follow.
🧨 And now for the forecast: Guidance Upgrade
ISRG is raising the bar for surgery volumes once again for the full year 2026:
- Procedure growth for FY2026: Increased to approx. 14.0% – 15.0% (previously set at a noticeably more conservative level).
- Gross Profit Margin: Expected to remain strong at 68.7% to 69.3%.
The market had previously expressed concerns about a slowdown in hospital investments—ISRG completely dispels these concerns with its financial results.
🧠da Vinci 5 → The new hardware cycle is getting underway
What’s exciting isn’t just the current business:
The rollout of the new da Vinci 5 (dV5) is gaining momentum at a breakneck pace. The new-generation systems offer significantly higher computing power, AI-powered data analytics, and feedback sensors for surgeons.
This cements ISRG’s global dominance and ensures that existing hospitals quickly upgrade their old da Vinci Xi fleets.
⚠️ But a risk assessment remains essential
The company’s operating performance is excellent.
But that is precisely why the market is scrutinizing its valuation so closely:
- Very high P/E ratio: ISRG has always traded at a massive quality premium (P/E ratio often >50).
- China default risk: A continued subdued consumer and fiscal environment in Asia, as well as attempts by local competitors to challenge the company.
- Budgetary pressure in the healthcare sector: General cost-cutting measures at U.S. hospitals could slow the initial adoption of systems.
⚡💡 The Bottom Line
Intuitive Surgical once again demonstrates who the undisputed king of robotic surgery is.
$3.05 billion in revenue. +21.5%.
$3.00 EPS (vs. $2.65 expected).
$1 billion net income in just one quarter.
18% growth in procedures.
Fundamentals: A top-notch earnings report. Competitive Advantage: Unassailable thanks to patents, software, and lock-in effects.Operating Leverage: Exemplary. Procedural Demand: No signs of weakness whatsoever. Rating: The only fly in the ointment.
Rating for the earnings report: 🟢🔥🔥🔥 “DOUBLE BEAT & PROCEDURE BOOST.”
